Although the present results glimpsed that the reinforcement of the COVID-19 standard therapy with two doses of HP in non-severe infected patients may have a tendency to reduce the probability of progression to a more severe presentation of the disease one week after the infusion of HP, the result’s interpretation should be considered with caution due to the early termination of the trial that caused a small sample size. This evidence concerns the gene HP and COVID-19.